Company news

Alkermes plc news in 2023

Alkermes plc's news releases, calls and decks from 2023, newest first.

View company

Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk

December 13, 2023

Alkermes Completes Separation of Oncology Business

November 14, 2023

Alkermes to Participate in the Jefferies London Healthcare Conference

November 6, 2023

Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement

October 30, 2023

Alkermes plc Reports Third Quarter 2023 Financial Results

October 24, 2023

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

October 22, 2023

Alkermes to Report Third Quarter Financial Results on October 25, 2023

October 17, 2023

Mural Oncology to Host Investor Webcast on October 17

October 9, 2023

Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

October 9, 2023

Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress

September 10, 2023

Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards® Program

September 6, 2023

Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants® Program

August 30, 2023

Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation

August 29, 2023

Alkermes plc Reports Second Quarter 2023 Financial Results

July 25, 2023

Alkermes to Report Second Quarter Financial Results on July 26, 2023

July 18, 2023

Alkermes Shareholders Re-Elect All Seven Company Director Nominees at 2023 Annual General Meeting of Shareholders

June 28, 2023

Independent Proxy Advisory Firm Glass Lewis Recommends Alkermes Shareholders Vote "FOR" All Seven of the Company's Highly Qualified Director Nominees

June 20, 2023

Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees' Election to Alkermes Board

June 19, 2023

Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors

June 12, 2023

Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation

June 7, 2023

Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations

June 5, 2023

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

May 31, 2023

Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value

May 24, 2023

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2023 Scientific Conferences

May 15, 2023

Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 8, 2023

Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process

May 7, 2023

Alkermes plc Reports First Quarter 2023 Financial Results

April 25, 2023

Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration

April 24, 2023

Alkermes to Report First Quarter Financial Results on April 26, 2023

April 18, 2023

Alkermes Announces Application Period for 2023 Alkermes Inspiration Grants® Program to Support Innovative Initiatives Focused on People Affected by Addiction, Serious Mental Illness or Cancer

April 18, 2023

Alkermes Announces Submission of Confidential Draft Form 10 Registration Statement for Planned Separation of Oncology Business

April 17, 2023

Journal of Clinical Psychiatry Publishes Data from Alkermes' ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their Illness

March 22, 2023

Alkermes to Participate in the Stifel 2023 CNS Days

March 14, 2023

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023

February 15, 2023

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023

February 8, 2023

Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma

January 16, 2023

Calls in 2023

Decks in 2023